Factors Associated with the Prescribing of High-Intensity Statins
Abstract
:1. Introduction
2. Experimental Section
2.1. Study Design and Participants
2.2. Data Sources and Variables
2.3. Analyses
2.4. Ethical Issues
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Piepoli, M.F.; Hoes, A.W.; Agewall, S.; Albus, C.; Brotons, C.; Catapano, A.L.; Cooney, M.T.; Corrà, U.; Cosyns, B.; Deaton, C.; et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2016, 37, 2315–2381. [Google Scholar] [CrossRef] [PubMed]
- Grundy, S.M.; Stone, N.J.; Bailey, A.L.; Beam, C.; Birtcher, K.K.; Blumenthal, R.S.; Braun, L.T.; de Ferranti, S.; Faiella-Tommasino, J.; Forman, D.E.; et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2019, 73, e285–e350. [Google Scholar] [CrossRef] [PubMed]
- Taylor, F.; Huffman, M.D.; Macedo, A.F.; Moore, T.H.M.; Burke, M.; Smith, G.D.; Ward, K.; Ebrahim, S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 2013, 2013, CD004816. [Google Scholar] [CrossRef] [PubMed]
- Mihaylova, B.; Emberson, J.; Blackwell, L.; Keech, A.; Simes, J.; Barnes, E.H.; Voysey, M.; Gray, A.; Collins, R.; Baigent, C.; et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380, 581–590. [Google Scholar] [CrossRef]
- Sniderman, A.; Thanassoulis, G.; Couture, P.; Williams, K.; Alam, A.; Furberg, C.D. Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists’ Collaboration meta-analysis for low-density lipoprotein lowering. J. Clin. Lipidol. 2012, 6, 303–309. [Google Scholar] [CrossRef]
- Law, M.R.; Wald, N.J.; Rudnicka, A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. Br. Med. J. 2003, 326, 1423–1427. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- National Institute for Health Care Excellence. Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification; NICE Clinical Guideline CG181; National Institute for Health Care Excellence: London, UK, 2016. [Google Scholar]
- Johal, S.; Jamsen, K.M.; Bell, J.S.; Mc Namara, K.P.; Magliano, D.J.; Liew, D.; Ryan-Atwood, T.E.; Anderson, C.; Ilomäki, J. Do statin users adhere to a healthy diet and lifestyle? The Australian diabetes, obesity and lifestyle study. Eur. J. Prev. Cardiol. 2017, 24, 621–627. [Google Scholar] [CrossRef]
- Sidell, M.A.; Ghai, N.R.; Reynolds, K.; Jacobsen, S.J.; Scott, R.; Van Den Eeden, S.; Caan, B.; Quinn, V.P. Statins as a free pass: Body mass index and other cardiovascular risk factors among lipid-lowering medication users and nonusers in the California Men’s Health Study. Prev. Med. 2019, 129, 105822. [Google Scholar] [CrossRef]
- Macías Saint-Gerons, D.; De La Fuente Honrubia, C.; Montero Corominas, D.; Gil, M.J.; De Andrés-Trelles, F.; Catalá-López, F. Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: A population-based study. Eur. J. Clin. Pharmacol. 2014, 70, 99–108. [Google Scholar] [CrossRef]
- Ho, K.; Jamsen, K.M.; Bell, J.S.; Korhonen, M.J.; Mc Namara, K.P.; Magliano, D.J.; Liew, D.; Ryan-Atwood, T.E.; Shaw, J.E.; Luc, S.; et al. Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia: The AusDiab study. Eur. J. Clin. Pharmacol. 2018, 74, 1493–1501. [Google Scholar] [CrossRef]
- Casasnovas, J.A.; Alcaide, V.; Civeira, F.; Guallar, E.; Ibañez, B.; Borreguero, J.J.; Laclaustra, M.; León, M.; Peñalvo, J.L.; Ordovás, J.M.; et al. Aragon workers’ health study—Design and cohort description. BMC Cardiovasc. Disord. 2012, 12, 45. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martin-Moreno, J.M.; Boyle, P.; Gorgojo, L.; Maisonneuve, P.; Fernandez-Rodriguez, J.C.; Salvini, S.; Willett, W.C. Development and validation of a food frequency questionnaire in Spain. Int. J. Epidemiol. 1993, 22, 512–519. [Google Scholar] [CrossRef] [PubMed]
- Martínez-González, M.A.; López-Fontana, C.; Varo, J.J.; Sánchez-Villegas, A.; Martinez, J.A. Validation of the Spanish version of the physical activity questionnaire used in the Nurses’ Health Study and the Health Professionals’ Follow-up Study. Public Health Nutr. 2005, 8, 920–927. [Google Scholar] [CrossRef] [PubMed]
- Laclaustra, M.; Casasnovas, J.A.; Fernández-Ortiz, A.; Fuster, V.; León-Latre, M.; Jiménez-Borreguero, L.J.; Pocovi, M.; Hurtado-Roca, Y.; Ordovas, J.M.; Jarauta, E.; et al. Femoral and Carotid Subclinical Atherosclerosis Association with Risk Factors and Coronary Calcium: The AWHS Study. J. Am. Coll. Cardiol. 2016, 67, 1263–1274. [Google Scholar] [CrossRef] [PubMed]
- Levey, A.S.; Bosch, J.P.; Lewis, J.B.; Greene, T.; Rogers, N.; Roth, D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999, 130, 461–470. [Google Scholar] [CrossRef] [PubMed]
- Levey, A.S.; Coresh, J.; Balk, E.; Kausz, A.T.; Levin, A.; Steffes, M.W.; Hogg, R.J.; Perrone, R.D.; Lau, J.; Eknoyan, G. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann. Intern. Med. 2003, 139, 137–147. [Google Scholar] [CrossRef] [PubMed]
- Friedewald, W.T.; Levy, R.I.; Fredrickson, D.S. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. Clin. Chem. 1972, 18, 499–502. [Google Scholar] [CrossRef]
- Fung, T.T.; Rexrode, K.M.; Mantzoros, C.S.; Manson, J.E.; Willett, W.C.; Hu, F.B. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation 2009, 119, 1093–1100. [Google Scholar] [CrossRef] [Green Version]
- Ainsworth, B.E.; Haskell, W.L.; Herrmann, S.D.; Meckes, N.; Bassett, D.R.; Tudor-Locke, C.; Greer, J.L.; Vezina, J.; Whitt-Glover, M.C.; Leon, A.S. 2011 compendium of physical activities: A second update of codes and MET values. Med. Sci. Sports Exerc. 2011, 43, 1575–1581. [Google Scholar] [CrossRef] [Green Version]
- León-Latre, M.; Moreno-Franco, B.; Andrés-Esteban, E.M.; Ledesma, M.; Laclaustra, M.; Alcalde, V.; Peñalvo, J.L.; Ordovás, J.M.; Casasnovas, J.A. Sedentarismo y su relación con el perfil de riesgo cardiovascular, la resistencia a la insulina y la inflamación. Rev. Esp. Cardiol. 2014, 67, 449–455. [Google Scholar] [CrossRef]
- Hirshkowitz, M.; Whiton, K.; Albert, S.M.; Alessi, C.; Bruni, O.; DonCarlos, L.; Hazen, N.; Herman, J.; Katz, E.S.; Kheirandish-Gozal, L.; et al. National sleep foundation’s sleep time duration recommendations: Methodology and results summary. Sleep Health 2015. [Google Scholar] [CrossRef] [PubMed]
- Conroy, R.M.; Pyörälä, K.; Fitzgerald, A.P.; Sans, S.; Menotti, A.; De Backer, G.; De Bacquer, D.; Ducimetière, P.; Jousilahti, P.; Keil, U.; et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur. Heart J. 2003, 24, 987–1003. [Google Scholar] [CrossRef]
- Sarwar, N.; Gao, P.; Kondapally Seshasai, S.R.; Gobin, R.; Kaptoge, S.; Di Angelantonio, E.; Ingelsson, E.; Lawlor, D.A.; Selvin, E.; Stampfer, M.; et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375, 2215–2222. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mira, J.J.; Nebot, C.; Lorenzo, S.; Pérez-Jover, V. Patient report on information given, consultation time and safety in primary care. Qual. Saf. Health Care 2010, 19, e33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Milà, L.; Barrabés, J.A.; Lidón, R.M.; Sambola, A.; Bañeras, J.; Oristrell, G.; Rafecas, A.; García-Dorado, D. Prior adherence to recommended lipid control targets in patients admitted for acute coronary syndrome. Rev. Esp. Cardiol. 2019. [Google Scholar] [CrossRef] [PubMed]
- Guallar-Castillón, P.; Gil-Montero, M.; León-Muñoz, L.M.; Graciani, A.; Bayán-Bravo, A.; Taboada, J.M.; Banegas, J.R.; Rodríguez-Artalejo, F. Magnitude and management of hypercholesterolemia in the adult population of Spain, 2008–2010: The ENRICA study. Rev. Esp. Cardiol. 2012, 65, 551–558. [Google Scholar] [CrossRef]
- Aguilar-Palacio, I.; Malo, S.; Feja, C.; Lallana, M.J.; León-Latre, M.; Casasnovas, J.A.; Rabanaque, M.; Guallar, E. Risk factors control for primary prevention of cardiovascular disease in men: Evidence from the Aragon Workers Health Study (AWHS). PLoS ONE 2018, 13, e0193541. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Malo, S.; Aguilar-Palacio, I.; Feja, C.; Menditto, E.; Lallana, M.J.; Andrade, E.; Casasnovas, J.A.; Rabanaque, M.J. Persistence With Statins in Primary Prevention of Cardiovascular Disease: Findings From a Cohort of Spanish Workers. Rev. Esp. Cardiol. 2018, 71, 26–32. [Google Scholar] [CrossRef]
- Laakso, M.; Kuusisto, J. Diabetes Secondary to Treatment with Statins. Curr. Diabetes Rep. 2017, 17, 10. [Google Scholar] [CrossRef]
Statin Intensity | ||||
---|---|---|---|---|
All (N = 683) | Low–Moderate-Intensity (N = 360) | High-Intensity (N = 323) | p | |
Sociodemographic | ||||
Mean (SD) age, y | 53.0 (4.0) | 52.8 (4.3) | 53.1 (3.7) | 0.390 |
Women, N (%) | 31 (4.5) | 18 (5.0) | 13 (4.0) | 0.585 |
Mean (SD) no. of years in factory | 28.4 (4.5) | 28.4 (4.9) | 28.4 (4.1) | 0.963 |
Work shift, N (%) | 0.137 | |||
Rotating | 522 (76.5) | 283 (78.8) | 239 (74.0) | |
Fixed | 160 (23.4) | 76 (21.2) | 84 (26.0) | |
Work type, N (%) | 0.117 | |||
Assembly line/manual | 590 (86.4) | 318 (88.3) | 272 (84.2) | |
Sedentary | 93 (13.6) | 42 (11.7) | 51 (15.8) | |
Clinical and anthropometric | ||||
BMI (kg/m2), N (%) | 0.600 | |||
<25 | 127 (18.6) | 67 (18.6) | 60 (18.6) | |
25–30 | 392 (57.4) | 212 (58.9) | 180 (55.7) | |
≥30 | 164 (24.0) | 81 (22.5) | 83 (25.7) | |
EGFR < 60 mL/min/1.73 m2, N (%) | 8 (1.2) | 6 (1.7) | 2 (0.6) | 0.292 |
Total cholesterol (mg/dL), mean (SD) | 246.9 (37.5) | 244.8 (35.0) | 249.2 (40.0) | 0.124 |
LDL-cholesterol (mg/dL), mean (SD) | 159.0 (33.2) | 157.7 (30.5) | 160.6 (36.0) | 0.258 |
HDL-cholesterol (mg/dL), mean (SD) | 52.2 (11.5) | 52.2 (11.4) | 52.2 (11.6) | 0.972 |
Triglycerides (mg/dL), mean (SD) | 187.8 (139.7) | 185.1 (148.5) | 190.7 (129.4) | 0.601 |
Diabetes, N (%) | 69 (10.1) | 33 (9.2) | 36 (11.2) | 0.392 |
Hypertension, N (%) | 354 (51.8) | 175 (48.6) | 179 (55.4) | 0.075 |
Rheumatoid arthritis, N (%) | 12 (1.8) | 5 (1.4) | 7 (2.2) | 0.563 |
Previous TIA, N (%) | 3 (0.4) | 2 (0.6) | 1 (0.3) | 1.000 |
Arrhythmia, N (%) | 15 (2.2) | 7 (1.9) | 8 (2.5) | 0.795 |
Statin Intensity | ||||
---|---|---|---|---|
All (N = 683) | Low–Moderate-Intensity (N = 360) | High-Intensity (N = 323) | p | |
Lifestyle | ||||
Smoking, N (%) | 0.678 | |||
Never | 131 (19.2) | 73 (20.3) | 58 (18.0) | |
Current | 249 (36.5) | 127 (35.3) | 122 (37.8) | |
Former | 302 (44.3) | 160 (44.4) | 142 (44.0) | |
Alcohol intake, N (%) | 0.685 | |||
Low risk (<40 g/d) | 581 (85.1) | 306 (85.0) | 275 (85.1) | |
Medium risk (40–60 g/d) | 64 (9.4) | 36 (10.0) | 28 (8.7) | |
High risk (>60 g/d) | 38 (5.6) | 18 (5.0) | 20 (6.2) | |
Mediterranean diet adherence, N (%) | 0.379 | |||
Low | 244 (35.7) | 131 (36.4) | 113 (35.0) | |
Medium | 372 (54.5) | 189 (52.5) | 183 (56.7) | |
High | 67 (9.8) | 40 (11.1) | 27 (8.4) | |
METs h/wk, mean (SD) | 31.0 (21.2) | 29.6 (20.4) | 32.6 (22.0) | 0.065 |
Sitting 5.5 h/day or more, N (%) | 361 (53.1) | 189 (52.5) | 172 (53.8) | 0.744 |
Sleep < 6 h/night, N (%) | 136 (20.0) | 64 (17.8) | 72 (22.4) | 0.130 |
Carotid atherosclerosis, N (%) | 273 (44.0) | 130 (40.1) | 143 (48.3) | 0.040 |
Femoral atherosclerosis, N (%) | 404 (65.6) | 204 (61.1) | 200 (70.9) | 0.010 |
Unadjusted Model | Multivariable Model | |
---|---|---|
OR (95%CI) | OR (95%CI) | |
Age (years) | ||
<50 | 0.90 (0.58–1.39) | 1.03 (0.65–1.62) |
50–55 | 1.00 | 1.00 |
55–60 | 0.88 (0.60–1.29) | 0.90 (0.60–1.34) |
>60 | 0.72 (0.25–2.09) | 0.63 (0.21–1.90) |
LDL-cholesterol (mg/dL) | ||
Non-diabetics | ||
<155 | 1.00 | 1.00 |
≥155 | 1.04 (0.73–1.49) | 1.03 (0.72–1.49) |
Diabetics | ||
<155 | 1.00 | 1.00 |
≥155 | 4.50 (1.19–16.99) | 4.96 (1.29–19.10) |
Hypertension | ||
No | 1.00 | 1.00 |
Yes | 1.25 (0.90–1.74) | 1.26 (0.89–1.79) |
Diabetes | ||
No | 1.00 | 1.00 |
Yes | 1.42 (0.78–2.56) | 1.45 (0.78–2.69) |
Smoking | ||
Never | 1.00 | 1.00 |
Current | 1.41 (0.88–2.25) | 1.24 (0.74–2.06) |
Former | 1.20 (0.76–1.90) | 1.13 (0.70–1.83) |
METs h/wk | ||
<20 | 1.00 | 1.00 |
20–40 | 0.90 (0.60–1.35) | 0.93 (0.62–1.41) |
>40 | 1.55 (1.03–2.32) | 1.65 (1.08–2.50) |
Carotid atherosclerosis | ||
No | 1.00 | 1.00 |
Yes | 1.33 (0.96–1.86) | 1.21 (0.85–1.71) |
Femoral atherosclerosis | ||
No | 1.00 | 1.00 |
Yes | 1.53 (1.08–2.17) | 1.45 (0.98–2.13) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chaure-Pardos, A.; Malo, S.; Rabanaque, M.J.; Arribas, F.; Moreno-Franco, B.; Aguilar-Palacio, I. Factors Associated with the Prescribing of High-Intensity Statins. J. Clin. Med. 2020, 9, 3850. https://doi.org/10.3390/jcm9123850
Chaure-Pardos A, Malo S, Rabanaque MJ, Arribas F, Moreno-Franco B, Aguilar-Palacio I. Factors Associated with the Prescribing of High-Intensity Statins. Journal of Clinical Medicine. 2020; 9(12):3850. https://doi.org/10.3390/jcm9123850
Chicago/Turabian StyleChaure-Pardos, Armando, Sara Malo, María José Rabanaque, Federico Arribas, Belén Moreno-Franco, and Isabel Aguilar-Palacio. 2020. "Factors Associated with the Prescribing of High-Intensity Statins" Journal of Clinical Medicine 9, no. 12: 3850. https://doi.org/10.3390/jcm9123850
APA StyleChaure-Pardos, A., Malo, S., Rabanaque, M. J., Arribas, F., Moreno-Franco, B., & Aguilar-Palacio, I. (2020). Factors Associated with the Prescribing of High-Intensity Statins. Journal of Clinical Medicine, 9(12), 3850. https://doi.org/10.3390/jcm9123850